Wide Ranks

KZR

Kezar Life Sciences, Inc.

7.40

Top Statistics
Market Cap 53 M Forward PE -0.8311 Revenue Growth 0.00 %
Current Ratio 9.58 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 0.9340 Enterprise / Revenue -13.13 Price To Sales Trailing12 Months 7.71
Profitability
Profit Margins 0.00 % Operating Margins -1422.01 %
Balance Sheet
Total Cash 164 M Total Cash Per Share 22.50 Total Debt 17 M
Total Debt To Equity 11.69 Current Ratio 9.58 Book Value Per Share 25.77
All Measures
Short Ratio 93.00 % Message Board Id finmb_304157325 Shares Short Prior Month 98290
Return On Equity -0.5148 City South San Francisco Uuid a58d540c-0082-3b09-9235-096cecf4e362
Previous Close 7.43 First Trade Date Epoch Utc 1 B Book Value 25.77
Beta 0.2170 Total Debt 17 M Volume 15933
Price To Book 0.2871 Last Split Date 1 B Fifty Two Week Low 5.20
Total Cash Per Share 22.50 Total Revenue 7 M Shares Short Previous Month Date 1 B
Target Median Price 14.50 Audit Risk 7 Max Age 86400
Recommendation Mean 2.33 Sand P52 Week Change 0.3133 Operating Margins -1422.01 %
Target Mean Price 14.50 Net Income To Common -98568000 Short Percent Of Float 0.0250
Implied Shares Outstanding 7 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 47380 Average Volume10days 47380 Total Cash 164 M
Next Fiscal Year End 1 B Revenue Per Share 0.9620 Held Percent Insiders 0.1479
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Share Holder Rights Risk 8 Regular Market Previous Close 7.43 Target Low Price 11.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 7.48 Open 7.44
Free Cashflow -41498624 State CA Dividend Yield 0.00 %
Return On Assets -0.2807 Time Zone Short Name EST Board Risk 7
Trailing Eps -13.12 Day Low 7.39 Address1 4000 Shoreline Court
Shares Outstanding 7 M Compensation Risk 10 Price Hint 2
Target High Price 18.00 Website https://www.kezarlifesciences.com 52 Week Change -0.1190
Average Volume 96545 Forward Eps -10.47 Recommendation Key buy
Compensation As Of Epoch Date 1 B Quick Ratio 948.10 % Last Split Factor 1:10
Regular Market Day High 7.50 Is_sp_500 False Profit Margins 0.00 %
Debt To Equity 11.69 Fifty Two Week High 11.40 Day High 7.50
Shares Short 177961 Regular Market Open 7.44 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue -13.13 Revenue Growth 0.00 %
Shares Percent Shares Out 0.0244 Operating Cashflow -79078000 Currency USD
Time Zone Full Name America/New_York Market Cap 53 M Is_nasdaq_100 False
Zip 94080 Quote Type EQUITY Industry Biotechnology
Long Name Kezar Life Sciences, Inc. Overall Risk 10 Regular Market Day Low 7.39
Held Percent Institutions 0.6390 Current Price 7.40 Address2 Suite 300
Enterprise To Ebitda 0.9340 Financial Currency USD Current Ratio 9.58
Industry Disp Biotechnology Number Of Analyst Opinions 2 Country United States
Float Shares 4 M Two Hundred Day Average 7.39 Governance Epoch Date 1 B
Enterprise Value -91923296 Price To Sales Trailing12 Months 7.71 Forward PE -0.8311
Regular Market Volume 15933 Ebitda -98462000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States.

The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.

Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics.

Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.